During the follow-up period , in the intention-to-treat analysis , 92 % of the patients receiving low-dose posaconazole and 81 % receiving high-dose posaconazole , as compared with 38 % receiving benznidazole , tested positive for T. cruzi DNA on rt-PCR assay ( P < 0.01 for the comparison of the benznidazole group with either posaconazole group ) ; in the per-protocol analysis , 90 % of the patients receiving low-dose posaconazole and 80 % of those receiving high-dose posaconazole , as compared with 6 % receiving benznidazole , tested positive on rt-PCR assay ( P < 0.001 for the comparison of the benznidazole group with either posaconazole group ) .